Why BerGenBio’s Bemcentinib Will Kick-Off UK’s COVID-19 ACCORD Program
New Direction For Phase II Anticancer Agent
There is strong scientific rationale from US and UK research to support evaluating the selective AXL kinase inhibitor bemcentinib in the UK’s early-stage clinical study program, ACCORD, a new initiative to find potential COVID-19 therapies.
You may also be interested in...
European biotech companies are finding diverse ways of finding support and financing to propel their potential first-in-class therapies into clinical studies, including sponsorship by patient charities as well as private placements.
BerGenBio of Norway has raised NOK75 million (about $12.5 million) from new and existing investors through a private placement. The privately held company's lead drug candidate is BGB324, a first-in-class selective Axl kinase inhibitor, which is currently in Phase Ib studies to treat different cancers as monotherapy and in combination with other drugs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.